株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

iPS細胞 (人工多能性幹細胞) の世界市場 - 業界レポート

Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report

発行 BIOINFORMANT WORLDWIDE, LLC 商品コード 935827
出版日 ページ情報 英文 238 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.69円で換算しております。
iPS細胞 (人工多能性幹細胞) の世界市場 - 業界レポート Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report
出版日: 2020年05月08日 ページ情報: 英文 238 Pages
担当者のコメント
2006年に人工多能性幹細胞(iPSC)が発見されて以降iPS細胞の臨床研究は拡大しており、CAR-T細胞の開発にも大きな効果をもたらしております。特にFUJIFILM CDI はこの市場の事業化の主要プレーヤーとして位置づけられており、世界中の研究者から注目されております。当レポートは市場予測他、iPSC lines、differentiated cells types、optimized reagents, protocols、differentiation kitsなど、最新の製品分析を行います。
概要

当レポートでは、世界のiPS細胞 (人工多能性幹細胞) 市場について調査分析し、概要、特許情勢、臨床試験、応用、主要企業などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 イントロダクション

第3章 iPS細胞 (人工多能性幹細胞) の歴史

  • 最初のiPS細胞の生成
  • 最初のヒトiPS細胞の生成
  • CiRAの生成
  • iPS細胞を使用した最初のハイスループットスクリーニング
  • 日本で承認された最初のiPS細胞の臨床試験、など

第4章 iPS細胞に関する研究発表

第5章 iPS細胞:特許情勢

  • タイムラインと特許の状況
  • 特許出願先
  • 特許出願先の動向、など

第6章 iPS細胞が関与する臨床試験

  • 現在の臨床試験の状況

第7章 iPS細胞に対する資金提供

  • iPS細胞に対するNIH資金額
  • iPS細胞のCIRM資金

第8章 iPS細胞の生成:概要

  • 再プログラム化因子
  • 遺伝子導入の4つの主要な方法の概要
  • 異なるベクトルタイプの有効性の比較
  • iPS細胞生成におけるゲノム編集技術

第9章 ヒトiPS細胞バンキング

  • iPS細胞バンキングの細胞源
  • iPS細胞バンキングで使用される再プログラム化法
  • iPS細胞バンクにおけるワークフロー
  • 既存のiPS細胞バンク

第10章 iPS細胞における生物医学的応用

第11章 iPS細胞におけるその他の新興応用

第12章 iPS細胞部門の取引

第13章 市場概要

第14章 企業プロファイル

図表

LIST OF FIGURES

  • FIGURE 2.1: The Share of iPSC-related Research Compared with other Stem Cell Types
  • FIGURE 2.2: Major Focuses of iPSC Companies
  • FIGURE 2.3: Commercially Available iPSC-Derived Cell Types
  • FIGURE 2.4: Relative Use of iPSC-Derived Cell Types in Toxicology/Safety Testing Assays
  • FIGURE 2.5: Toxicology/Safety Testing Assays using iPSC-Derived Cell Types
  • FIGURE 3.1: CiRA's Budget of ¥6.37 Billion
  • FIGURE 4.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2020
  • FIGURE 4.2: Percent Share of Published Articles by Research Themes
  • FIGURE 4.3: Percent Share of Published Articles by Disease Type
  • FIGURE 4.4: Percent Share of iPSC Research Publications by Country
  • FIGURE 5.1: Number of Patents Granted, Being Sought and “Dead”
  • FIGURE 5.2: Patent Families by Filing Jurisdiction
  • FIGURE 5.3: Patent Families by Applicant Origin
  • FIGURE 5.4: Top Ten Global Applicants
  • FIGURE 5.5: Top Ten Global Collaborators on PSC/iPSC Patents
  • FIGURE 5.6: Share of Patents on iPSC Preparation Technologies by Geography
  • FIGURE 5.7: Percent Share of iPSC Preparation Methods in the U.S., Japan and Europe
  • FIGURE 5.8: Percent Share of Patents Related to Cell Types Differentiated from iPSCs
  • FIGURE 5.9: Percent Share of Patent Applications for Disease-Specific Cell Technologies
  • FIGURE 5.10: Percent Share of Patents Representing Different Disorders
  • FIGURE 6.1: Number of Clinical Trials Involving iPSCs by Year, 2006-2020
  • FIGURE 6.2: Clinical Trials Involving iPSCs by Major Diseases
  • FIGURE 6.3: Clinical Trials Involving iPSCs by Country
  • FIGURE 7.1: Number of NIH Funding for iPSC Projects, 2010-2020
  • FIGURE 7.2: Value of NIH Funding for iPSCs by Year, 2010-2020
  • FIGURE 8.1: Overview of iPSC Technology
  • FIGURE 8.2: Generation of iPSCs from MEF Cultures through 24 Factors by Yamanaka
  • FIGURE 8.3: The Roles of OSKM Factors in the Induction of iPSCs
  • FIGURE 8.4: Schematic Representation of Delivery Methods for iPSCs Induction
  • FIGURE 8.5: Overview of Four Key Methods of Gene Delivery
  • FIGURE 9.1: Workflow in iPSC Banks
  • FIGURE 10.1: Biomedical Applications of iPSCs
  • FIGURE 10.2: Relative Use of iPSC-Derived Cell Types in Toxicity Testing
  • FIGURE 10.3: A Schematic for iPSC-Based Disease Modeling
  • FIGURE 10.4: Proportion of iPS Cell Lines Generated by Disease Type
  • FIGURE 10.5: Proportion of iPSC Sources in Cardiac Studies
  • FIGURE 10.6: Proportion of Vector Types used in Reprogramming
  • FIGURE 10.7: The Proportion of Differentiated Cardiomyocyte Types
  • FIGURE 10.8: Schematic for iPSC-Based Cell Therapy
  • FIGURE 11.1: Schematic Representation of Printing Techniques used for iPSC Bioprinting
  • FIGURE 11.2: Schematic Showing the use of iPSCs in Protecting Endangered Species
  • FIGURE 11.3: Funding raised by Cultured Meat Companies, 2016-2019
  • FIGURE 11.4: Estimated Global Market for Cultured Meat, 2023-2030
  • FIGURE 13.1: Estimated Global Market for iPSCs by Geography through 2026
  • FIGURE 13.2: Estimated Global Market for iPSCs by Technology through 2026
  • FIGURE 13.3: Estimated Global Market for iPSCs by Biomedical Application through 2026
  • FIGURE 13.4: Estimated Global Market Share for Differentiated Cell Types, 2020
  • FIGURE 14.1: Comparison of Conventional Meat Production and Cultured Meat Production

LIST OF TABLES

  • TABLE 2.1: Commercially Available iPSC Technologies
  • TABLE 2.2: Advantages and Limitations of iPSC Technology
  • TABLE 3.1: Timeline of the Most Important Milestones in iPSC Research, 2006-2019
  • TABLE 4.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2020
  • TABLE 5.1: Patent Families by Filing Jurisdiction
  • TABLE 5.2: Patents Granted and Patents Pending in the Global Patent Landscape
  • TABLE 6.1: Clinical Trials involving iPSCs as of March 2020
  • TABLE 6.1: (CONTINUED)
  • TABLE 6.1: (CONTINUED)
  • TABLE 6.1: (CONTINUED)
  • TABLE 6.1: (CONTINUED)
  • TABLE 6.1: (CONTINUED)
  • TABLE 6.1: (CONTINUED)
  • TABLE 7.1: NHI's Intended Funding Through its Component Organizations in 2020
  • TABLE 7.2: NIH Funding for Select Universities/Organizations for iPSC Studies
  • TABLE 7.2: (CONTINUED)
  • TABLE 7.3: CIRM Funding for Clinical Trials Involving iPSCs
  • TABLE 7.3: (CONTINUED)
  • TABLE 8.1: The Characterization of iPSCs
  • TABLE 8.2: Reprogramming Factors used in the Generation of iPSCs
  • TABLE 8.3: Different Cell Sources and Different Combinations of Reprogramming Factors
  • TABLE 8.1: Comparative Effectiveness of Different Vector Types
  • TABLE 8.2: iPSC Disease Models using Isogenic Control Lines Generated by CRISPR/Cas9
  • TABLE 8.2: (CONTINUED)
  • TABLE 9.1: Cell Sources and Reprogramming Agents used in iPSCs Banks
  • TABLE 9.2: Diseased iPSC Lines Available in CIRM Repository
  • TABLE 9.3: CIRMS' iPSC Initiative Awards
  • TABLE 9.4: Research Grade iPSCs Available with RMP
  • TABLE 9.5: Research Grade iPSC Lines for Orphan and Rare Diseases Available with RMP
  • TABLE 9.6: SCTL's Collaborations
  • TABLE 9.7: A Partial List of iPSC Lines Available with EBiPC
  • TABLE 9.8: List of Disease-Specific iPSCs Available with RIKEN
  • TABLE 9.8: (CONTINUED)
  • TABLE 9.8: (CONTINUED)
  • TABLE 9.9: An Overview of iPSC Banks Worldwide
  • TABLE 10.1: Providers of iPS Cell Lines and Parts Thereof for Research
  • TABLE 10.2: Comparison of hiPSC-Based & Animal-Based Drug Discovery
  • TABLE 10.3: Drug Discovery for Cardiovascular Diseases using iPSCs
  • TABLE 10.3: (CONTINUED)
  • TABLE 10.4: Drug Discovery for Neurological and Neuropsychiatric Diseases using iPSCs
  • TABLE 10.4: (CONTINUED)
  • TABLE 10.5: Drug Discovery for Rare Diseases using iPSCs
  • TABLE 10.5: (CONTINUED)
  • TABLE 10.6: Examples of Drug testing in iPSC-Derived Disease Models
  • TABLE 10.6: (CONTINUED)
  • TABLE 10.7: Published Human iPSC Disease Models
  • TABLE 10.7: (CONTINUED)
  • TABLE 10.7: (CONTINUED)
  • TABLE 10.7: (CONTINUED)
  • TABLE 10.7: (CONTINUED)
  • TABLE 10.8: Partial List of Cardiovascular and Related Diseases Modeled with iPSCs
  • TABLE 10.9: iPSC-Derived Organoids for Modeling Development and Disease
  • TABLE 10.10: Liver Diseases and Therapeutic Interventions Modeled using iPSCs
  • TABLE 10.10: (CONTINUED)
  • TABLE 10.11: Examples of iPSC-Based Neurodegenerative Disease Modeling
  • TABLE 10.11: (CONTINUED)
  • TABLE 10.11: (CONTINUED)
  • TABLE 10.11: (CONTINUED)
  • TABLE 10.12: Cancer-Derived iPSCs
  • TABLE 10.13: Clinical Trials for the Therapeutic Application of iPSC Derivatives, 2013-2019
  • TABLE 10.13: (CONTINUED)
  • TABLE 10.14: U.S. Clinical Trials Involving iPSCs
  • TABLE 10.14: (CONTINUED)
  • TABLE 11.1: Features of Different Bioprinting Techniques
  • TABLE 11.2: Bioprinting of iPSC-Derived Tissues
  • TABLE 11.3: Timeline of Achievements Made using iPSCs for Conservation of Animals
  • TABLE 11.14: Companies Working on Meat Production based on Cellular Agriculture
  • TABLE 13.1: Estimated Global Market for iPSCs by Geography, 2019-2026
  • TABLE 13.2: Estimated Global Market for iPSCs by Technology, 2019-2026
  • TABLE 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2019-2026
  • TABLE 13.4: Estimated Global Market for iPSCs by Differentiated Cell Types, 2019-2026
  • TABLE 14.1: iPS Cell Lines from CET
目次

Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. Therapeutic applications of iPSCs are also emerging.

2013 was a landmark year in Japan, because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD.

Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its “off-the-shelf&tdquo; iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.

iPS Cell Market Competitors

Today, FUJIFILM CDI has emerged as one of the largest commercial players within the iPSC sector. FUJIFILM CDI was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever. The feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan.

In 2009, ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University, made iPSC products commercially available for the first time with the launch of its human iPSC-derived cardiomyocytes, which it called ReproCario.

A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays, but after Yamanaka's iPSC technology became available, it became the first European company to license it in 2010. Ncardia's focus is on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells.

In total, at least 68 distinct market competitors now offer various types of iPSC products, services, technologies and therapies.

iPS Cell Commercialization

Methods of commercializing induced pluripotent stem cells (iPSCs) are diverse and continue to expand.

iPSC cell applications include, but are not limited to:

  • Research Products: Market competitors provide iPSC specific tools to scientists worldwide, including human iPSC lines and differentiated cells types, as well as optimized reagents, protocols, differentiation kits and more.
  • Drug Development & Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
  • Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • Toxicology Screening: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
  • Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies has added a new dimension to personalized medicine.
  • Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish.&tdquo;
  • Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors.
  • Other Applications: Other applications for iPSCs include areas like tissue engineering, 3D bioprinting, clean meat production, wildlife conservation and more.

Since the discovery of iPSC technology nearly 15 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.

Thus, the main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies and clinical trials for the development of iPSC-based therapeutics.

Importantly, the report presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type and Geography (North America, Europe, Asia/Pacific, and RoW). It also presents total market size figures and growth rates through 2026.

In addition to the primary and secondary research required for this report, interviews were conducted with notable iPSC industry leaders, including:

  • Kaz Hirao, President and COO of FUJIFILM CDI
  • Ross Macdonald, CEO of Cynata Therapeutics
  • Robin Smith, CEO of ORIG3N
  • Paul Wotton, Board Member of Cynata Therapeutics
  • And More

Claim this global strategic report to become immediately informed about the iPSC market, without sacrificing weeks of unnecessary research or being at risk of missing critical market opportunities.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary

2. INTRODUCTION

  • 2.1. Discovery of iPSCs
  • 2.2. Barriers in iPSC Application
  • 2.3. Timeline and Cost of iPSC Development
  • 2.4. Current Status of iPSCs Industry
    • 2.4.1. The Share of iPSC-based Research in the Overall Stem Cell Industry
    • 2.4.2. Major Focuses of iPSC Companies
    • 2.4.3. Commercially Available iPSC-Derived Cell Types
    • 2.4.4. Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays
    • 2.4.5. Toxicology/Safety Testing Assays using iPSC-Derived Cell Types
  • 2.5. Currently Available iPSC Technologies
  • 2.6. Advantages and Limitations of iPSCs Technology

3. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

  • 3.1. First iPSC generation from Mouse Fibroblasts, 2006
  • 3.2. First Human iPSC Generation, 2007
  • 3.3. Creation of CiRA, 2010
  • 3.4. First High-Throughput screening using iPSCs, 2012
  • 3.5. First iPSCs Clinical Trial Approved in Japan, 2013
  • 3.6. The First iPSC-RPE Cell Sheet Transplantation for AMD, 2014
  • 3.7. EBiSC Founded, 2014
  • 3.8. First Clinical Trial using Allogeneic iPSCs for AMD, 2017
  • 3.9. Clinical Trials for Parkinson's disease using Allogeneic iPSCs, 2018
  • 3.10. Commercial iPSC Plant SMaRT Established, 2018
  • 3.11. First iPSC Therapy Center in Japan, 2019

4. RESEARCH PUBLICATIONS ON IPSCS

  • 4.1. Categories of Research Publications
  • 4.2. Percent Share of Published Articles by Disease Type
  • 4.3. Number of Articles by Country

5. IPSCS: PATENT LANDSCAPE

  • 5.1. Timeline and Status of Patents
  • 5.2. Patent Filing Destinations
    • 5.2.1. Patent Applicant's Origin
    • 5.2.2. Top Ten Global Patent Applicants
    • 5.2.3. Collaborating Applicants of Patents
  • 5.3. Patent Application Trends iPSC Preparation Technologies
  • 5.4. Patent Application Trends in iPSC Differentiation Technologies
  • 5.5. Patent Application Trends in Disease-Specific Cell Technologies

6. CLINICAL TRIALS INVOLVING IPSCS

  • 6.1. Current Clinical Trials Landscape
    • 6.1.1. Clinical Trials Involving iPSCs by Major Diseases
    • 6.1.2. Clinical Trials Involving iPSCs by Country

7. FUNDING FOR IPSC

  • 7.1. Value of NIH Funding for iPSCs
    • 7.1.1. NHI's Intended Funding Through its Component Organizations in 2020
    • 7.1.2. NIH Funding for Select Universities for iPSC Studies
  • 7.2. CIRM Funding for iPSCs

8. GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW

  • 8.1. Reprogramming Factors
    • 8.1.1. Pluripotency-Associated Transcription Factors
    • 8.1.2. Different Cell Sources and Different Combinations of Factors
    • 8.1.3. Delivery of Reprogramming Factors
    • 8.1.4. Integrative Delivery Systems
      • 8.1.4.1. Integrative Viral Vectors
      • 8.1.4.2. Integrative Non-Viral Vectors
    • 8.1.5. Non-Integrative Delivery Systems
      • 8.1.5.1. Non-Integrative Viral Vectors
      • 8.1.5.2. Non-Integrative Non-Viral Delivery
  • 8.2. Overview of Four Key Methods of Gene Delivery
  • 8.3. Comparative Effectiveness of Different Vector Types
  • 8.4. Genome Editing Technologies in iPSCs Generation

9. HUMAN IPSC BANKING

  • 9.1. Cell Sources for iPSCs Banking
  • 9.2. Reprogramming methods used in iPSC Banking
    • 9.2.1. Factors used in reprogramming by Different Banks
  • 9.3. Workflow in iPSC Banks
  • 9.4. Existing iPSC Banks
    • 9.4.1. California Institute for Regenerative Medicine (CIRM)
      • 9.4.1.1. CIRM iPSC Repository
      • 9.4.1.2. CIRMS' Key Partnerships for iPSCs Repository
    • 9.4.2. Regenerative Medicine Program (RMP)
      • 9.4.2.1. Research Grade iPSC Lines for Orphan and Rare Diseases from RMP
      • 9.4.2.2. RMP's Stem Cell Translation Laboratory (SCTL)
    • 9.4.3. Center for iPS Cell Research and Application (CiRA)
      • 9.4.3.1. FiT: Facility for iPS Cell Therapy
    • 9.4.4. European Bank for Induced Pluripotent Stem Cells (EBiPC)
    • 9.4.5. Korean Society for Cell Biology (KSCB)
    • 9.4.6. Human Induced Pluripotent Stem Cell Intitiative (HipSci)
    • 9.4.7. RIKEN - BioResource Research Center (BRC)
    • 9.4.8. Taiwan Human Disease iPSC Consortium
    • 9.4.9. WiCell

10. BIOMEDICAL APPLICATIONS OF IPSCS

  • 10.1. iPSCs in Basic Research
    • 10.1.1. Understanding Cell Fate Control
    • 10.1.2. Cell Rejuvenation
    • 10.1.3. Studying Pluripotency
    • 10.1.4. Tissue and Organ Development and Physiology
    • 10.1.5. Generation of Human Gametes from iPSCs
    • 10.1.6. Providers of iPSC-Related Services for Researchers
  • 10.2. iPSCs in Drug Discovery
    • 10.2.1. Drug Discovery for Cardiovascular Disease using iPSCs
    • 10.2.2. Drug Discovery for Neurological and Neuropsychiatric Diseases
    • 10.2.3. Drug Discovery for Rare Diseases using iPSCs
  • 10.3. iPSCs in Toxicology Studies
    • 10.3.1. Relative Use of iPSC-Derived Cell Types in Toxicity Testing
  • 10.4. iPSCs in Disease Modeling
    • 10.4.1. Cardiovascular Diseases Modeled with iPSCs
    • 10.4.2. Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
    • 10.4.3. Proportion of iPSC Sources in Cardiac Studies
    • 10.4.4. Proportion of Vector Types used in Reprogramming
    • 10.4.5. Proportion of Differentiated Cardiomyocytes used in Disease Modeling
    • 10.4.6. iPSC-Derived Organoids for Modeling Development and Disease
    • 10.4.7. Modeling Liver Diseases using iPSC-derived Hepatocytes
    • 10.4.8. iPSCs in Neurodegenerative Disease Modeling
    • 10.4.9. Cancer-Derived iPSCs
  • 10.5. iPSCs in Cell-Based Therapies
    • 10.5.1. Ongoing Clinical Trials using iPSCs in Cell Therapy
      • 10.5.1.1. Clinical Trials for AMD
      • 10.5.1.2. Autologous iPSC-RPE for AMD
      • 10.5.1.3. Allogeneic iPSC-RPE for AMD
      • 10.5.1.4. iPSC-Derived Dopaminergic Neurons for Parkinson's disease
      • 10.5.1.5. iPSC-Derived NK Cells for Solid Cancers
      • 10.5.1.6. iPSC-derived Cells for GvHD
      • 10.5.1.7. iPSC-derived Cells for Spinal Cord Injury
      • 10.5.1.8. iPSC-derived Cardiomyocytes for Ischemic Cardiomyopathy
    • 10.5.2. Leaders in iPSC-Based Cell Therapies

11. OTHER NOVEL APPLICATIONS OF IPSCS

  • 11.1. iPSCs in Tissue Engineering
    • 11.1.1. 3D Bioprinting Techniques
    • 11.1.2. Biomaterials
    • 11.1.3. 3D Bioprinting Strategies
    • 11.1.4. Bioprinting Undifferentiated iPSCs
    • 11.1.5. Bioprinting iPSC-Differentiated Cells
  • 11.2. iPSCs in Animal Conservation
    • 11.2.1. iPSC Lines for the Preservation of Endangered Species of Animals
    • 11.2.2. iPSCs in Wildlife Conservation
  • 11.3. iPSCs and Cultured Meat
    • 11.3.1. Funding Raised by Cultured Meat Companies
    • 11.3.4. Global Market for Cultured Meat

12. DEALS IN IPSCS SECTOR

  • 12.1. $250 million Raised by Century Theraputics
  • 12.2. BlueRock Therapeutics Launched with $225 Million
  • 12.3. Collaboration between Allogene Therapeutics and Notch Therapeutics
  • 12.4. Acquisition of Semma Therapeutics by Vertex Therapeutics
  • 12.5. Evotec's Extended Collaboration with BMS
  • 12.6. Licensing Agreement between Allele Biotechnology and Astellas Pharma
  • 12.7. Codevelopment Agreement between Allele & SCM Lifesciences
  • 12.8. Fate Therapeutics Signs $100 Million Deal with Janssen
  • 12.9. Allele's Deal with Alpine Biotherapeutics
  • 12.10. Editas and BlueRock's Development Agreement

13. MARKET OVERVIEW

  • 13.1. Global Market for iPSCs by Geography
  • 13.2. Global Market for iPSCs by Technology
  • 13.3. Global Market for iPSCs by Biomedical Application
  • 13.4. Global Market for iPSCs by Cell Types
  • 13.5. Market Drivers
  • 13.6. Market Restraints
    • 13.6.1. Economic Issues
    • 13.6.2. Genomic Instability
    • 13.6.3. Immunogenicity
    • 13.6.4. Biobanking of iPSCs

14. COMPANY PROFILES

  • 14.1. Addgene, Inc.
    • 14.1.1. Viral Plasmids
  • 14.2. Aleph Farms
  • 14.3. Allele Biotechnology and Pharmaceuticals, Inc.
    • 14.3.1. iPSC Reprogramming and Differentiation
  • 14.4. AMS Biotechnology Europe, Ltd. (AMSBIO)
    • 14.4.1. Services
    • 14.4.2. Products
    • 14.4.3. Corneal Epithelial Cells Cultured in StemFit in Clinical Trials
  • 14.5. ALSTEM, INC.
    • 14.5.1. Products
    • 14.5.2. Services
  • 14.6. Applied Biological Materials, Inc. (ABM)
    • 14.6.1. Gene Expression Vectors and Viruses
  • 14.7. Applied StemCell, Inc.
    • 14.7.1. Services & Products
  • 14.8. American Type Culture Collection (ATCC)
    • 14.8.1. Product
  • 14.9. Applied StemCell (ASC), Inc.
    • 14.9.1. Products
  • 14.10. Aruna Bio, Inc.
    • 14.10.1. Program in Stroke
    • 14.10.2. Exosomes as Therapeurics
  • 14.11. Aspen Neuroscience, Inc.
    • 14.11.1. Technology
  • 14.12. Axol Bioscience, Ltd
    • 14.12.1. iPSC-derived Cells
    • 14.12.2. Disease Models
    • 14.12.3. Primary Cells
    • 14.12.4. Media & Reagents
    • 14.12.5. Services
  • 14.13. Beckman Coulter Life Sciences
    • 14.13.1. Cell Counters, Sizers and Media Analyzers
  • 14.14. BD Biosciences
    • 14.14.1. Products
  • 14.15. BioCat GmbH
    • 14.15.1. Products & Services
  • 14.16. BlueRock Therapeutics
    • 14.16.1. CELL + GENE Platform
  • 14.17. BrainXell
    • 14.17.1. Products
  • 14.18. Cellaria
    • 14.18.1. Product
  • 14.19. Cell Biolabs, Inc.
    • 14.19.1. Products
  • 14.20. CellGenix GmbH
    • 14.20.1. Products
  • 14.21. Cell Signaling Technology
    • 14.21.1. Products
  • 14.22. Cellular Engineering Technologies (CET)
    • 14.22.1. iPS Cell Lines
  • 14.23. Cellular Dynamics International, Inc.
    • 14.23.1. Products
  • 14.24. Censo Biotechnologies, Ltd.
    • 14.24.1. Human iPSC Reprogramming Services
    • 14.24.2. iPSC Gene Editing Services
    • 14.24.3. iPSC Target Validation and Assay Services
  • 14.25. Century Therapeutics, LLC
    • 14.25.1. Allogeneic Immune Cell Therapy
  • 14.26. CiRA
    • 14.26.1. Collaborations
  • 14.27. Corning, Inc.
    • 14.27.1. Products
  • 14.28. Creative Bioarray
    • 14.28.1. Products
  • 14.29. Cynata Therapeutics Ltd.
    • 14.29.1. Cymerus MSCs
  • 14.30. Cytovia Therapeutics
    • 14.30.1. iPSC CAR NK Cells
  • 14.31. DefiniGEN
    • 14.31.1. OptiDIFF iPSC Platform
    • 14.31.2. Service
    • 14.31.3. Patient-Derived Custom Cell Lines
    • 14.31.4. Hepatocytes WT
    • 14.31.5. Hepatocyte A1ATD
    • 14.31.6. Hepatocyte GSD1a
    • 14.31.7. Hepatocyte NAFLD
    • 14.31.8. Hepatocyte FH
    • 14.31.9. Pancreatic WT
    • 14.31.10. Pancreatic MODY3
  • 14.32. Fate Therapeutics, Inc.
    • 14.32.1. iPSC Platform
    • 14.32.2. Collaboration with ONO Pharmaceutical Co., Ltd.
    • 14.32.3. Collaboration with Memorial Sloan-Kettering Cancer Center
    • 14.32.4. Collaboration with University of California, San Diego
    • 14.32.5. Collaboration with Oslo University Hospital
  • 14.33. FUJIFILM Cellular Dynamics, Inc.
    • 14.33.1. iCell Products
    • 14.33.2. MyCell Products
    • 14.33.3. FCDI's Partners & Providers
    • 14.33.4. Groundbreaking Cellular Therapy Applications
    • 14.33.5. New Paradigm for Drug Discovery
    • 14.33.6. FCDI & Stem Cell Banking
  • 14.34. GeneCopoeia, Inc.
    • 14.34.1. Products & Services
  • 14.35. GenTarget, Inc.
    • 14.35.1. Products
    • 14.35.2. Services
  • 14.36. Heartseed, Inc.
    • 14.36.1. Technology
  • 14.37. InvivoGen
    • 14.37.1. Products
  • 14.38. iPS Portal, Inc.
    • 14.38.1. Services
  • 14.39. iXCells Biotechnologies
    • 14.39.1. Products
  • 14.40. Lonza Group, Ltd.
    • 14.40.1. Nucleofector Technology
  • 14.41. Merck/Sigma Aldrich
    • 14.41.1. Products
  • 14.42. Megakaryon Corporation
    • 14.42.1. Technology
  • 14.43. Metrion Biosciences, Ltd.
    • 14.43.1. Cardiac Translational Assays
  • 14.44. Miltenyi Biotec B.V. & Co. KG
    • 14.44.1. Cell Manufacturing Platform
  • 14.45. Ncardia
    • 14.45.1. iPSC Solutions for Cell Therapy
    • 14.45.2. Drug Safety and Toxicity Services
  • 14.46. NeuCyte
    • 14.46.1. Technology
  • 14.47. Newcells Biotech
    • 14.47.1. Expertise
    • 14.47.2. iPSC Reprogramming Services
    • 14.47.3. Assay Products and Services
    • 14.47.4. Assay Development
  • 14.48. PeproTech
    • 14.48.1. Products
  • 14.49. Phenocell SAS
    • 14.49.1. Human iPSCs
  • 14.50. Platelet BioGenesis
    • 14.50.1. Technology
  • 14.51. Pluricell Biotech
    • 14.51.1. Pluricell's Projects
  • 14.52. PromoCell GmbH
    • 14.52.1. Products
  • 14.53. Qiagen
    • 14.53.1. Single Cell Analysis
  • 14.54. R&D Systems, Inc.
    • 14.54.1. Products
  • 14.55. ReproCELL
    • 14.55.1. Services
    • 14.55.2. Products
  • 14.56. STEMCELL Technologies
    • 14.56.1. Products
  • 14.57. Stemina Biomarker Discovery
    • 14.57.1. Cardio quickPredict
    • 14.57.2. devTOX quickPredict
  • 14.58. Synthego Corp.
    • 14.58.1. CRISPR-Edited iPSCs
  • 14.59. System Biosciences (SBI)
    • 14.59.1. Products
  • 14.60. Takara Bio
    • 14.60.1. Stem Cell Research Products
  • 14.61. Takeda Pharmaceutical Co., Ltd.
    • 14.61.1. Collaboration between CiRA and Takeda
    • 14.61.2. FUJIFILM's Collaboration with Takeda
  • 14.62. Tempo Bioscience
    • 14.62.1. Human Cell Models
  • 14.63. Thermo Fisher Scientific, Inc.
    • 14.63.1. Products for Stem Cell Culture
    • 14.63.2. Products for Stem Cell Characterization
    • 14.63.3. Products for Stem Cell Engineering
  • 14.64. TreeFrog Therapeutics
    • 14.64.1. C-Stem Technology
  • 14.65. VistaGen Therapeutics, Inc.
    • 14.65.1. CardioSafe 3D
  • 14.66. Waisman Biomanufacturing
    • 14.66.1. GMP iPSCs
  • 14.67. xCell Science, Inc.
    • 14.67.1. Control Lines
    • 14.67.2. Products
    • 14.67.3. Services
  • 14.68. Yashraj Biotechnology, Ltd.
    • 14.68.1. Products and Services for Drug Discovery